8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2016

ALIMERA SCIENCES, INC.(Exact name of registrant as specified in its charter)

Delaware	001-34703		20-0028718
(State or other Jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)
6120 Windward Parkway Suite 290 Alpharetta, Georgia		30005
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On August 3, 2016, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the second quarter ended June 30, 2016. Alimera will be hosting a conference call, as well as a live webcast on the Investor Relations section of its corporate website at www.alimerasciences.com, on August 4, 2016 at 10:00 A.M. ET to discuss its second quarter ended June 30, 2016 financial results and to provide regulatory and commercial updates. The full text of the press release, which includes information regarding Alimera’s use of non-GAAP financial measures, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Various statements to be made during the conference call and webcast, including the slide deck presentation discussed in Item 7.01 of this Current Report on Form 8-K, are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for significant growth and market penetration of ILUVIEN, that Alimera’s refinancing plans will provide additional liquidity and improved financial flexibility, that the waiver will allow Alimera additional time to accomplish its refinancing plans and Alimera’s belief that only one Phase 3 clinical trial will be able to establish adequate evidence of safety and efficacy for ILUVIEN and obtain FDA approval for additional indications of ILUVIEN. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplate,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Alimera's ability to close on additional or alternative debt or equity financing in an appropriate fashion, Alimera failing to meet its financial covenants under its amended loan facility with Hercules Capital, Inc., which could materially affect Alimera’s commercialization of ILUVIEN, market acceptance of ILUVIEN in the U.S. and Europe, including physicians' ability to obtain reimbursement and seasonality, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the Securities and Exchange Commission (“SEC”) and available free of charge on the SEC’s website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera’s Quarterly Report on Form 10-Q for the six months ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements made during the conference call and webcast are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date on which they are made (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD.

Alimera is furnishing under this Item 7.01 a copy of a slide deck presentation which will be available August 4, 2016 on Alimera’s earnings webcast for the second quarter ended June 30, 2016. The presentation is incorporated by reference herein. Certain financial information relating to completed fiscal periods that will be part of the earnings webcast is included in the presentation that will accompany the earnings webcast, a copy of which is attached hereto as Exhibit 99.2. The earnings webcast will include certain non-GAAP financial measures. Reconciliations of these non-GAAP

financial measures to the comparable measures calculated and presented in accordance with GAAP are included in Alimera’s press release issued August 3, 2016 and attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01, including Exhibit 99.2 attached hereto and incorporated herein, is being “furnished” and not “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act, unless specifically identified as being incorporated therein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.	Description
99.1	Press Release of Alimera Sciences, Inc. dated August 3, 2016
99.2	Set of slides that will accompany the August 4, 2016 earnings webcast

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALIMERA SCIENCES, INC.
Dated: August 3, 2016	By:	/s/ RICHARD S. EISWIRTH, JR.
	Name:	Richard S. Eiswirth, Jr.
	Title:	President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Alimera Sciences, Inc. dated August 3, 2016
99.2	Set of slides that will accompany the August 4, 2016 earnings webcast

EX-99.1

Exhibit 99.1

Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update

Strong revenue gains in the second quarter of 2016, U.S. ILUVIEN volume significantly increased

Over 6,000 eyes treated with ILUVIEN to date

Positive discussions with the FDA regarding future potential indications for ILUVIEN

Alimera to host conference call on August 4, 2016 at 10:00 AM ET

ATLANTA, August 3, 2016 /GLOBENEWSWIRE/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the quarter ended June 30, 2016.

Second Quarter Highlights

• Second quarter 2016 global revenue increased 66% compared to the second quarter of 2015

• U.S. revenue increased 89% in the second quarter of 2016 compared to the second quarter 2015

• Discussions with the U.S. Food and Drug Administration (FDA) regarding potential future indications for the treatment of retinal vein occlusion and non-proliferative diabetic retinopathy

"We are pleased with the sales of ILUVIEN in the second quarter of 2016 which indicate that we are gaining traction in the marketplace," said Dan Myers, Chief Executive Officer of Alimera. "ILUVIEN is a very different way to treat diabetic macular edema and we believe that we are just beginning to see the potential of the ILUVIEN market opportunity. With more peer to peer engagement at upcoming annual retina meetings and continued education of physicians, we believe we will see the adoption of ILUVIEN increase, opening the door for significant growth and market penetration. We are also very excited by our dialogue with the FDA regarding potential opportunities to expand the indications for ILUVIEN." 

Expanding Indications for ILUVIEN

Alimera has engaged in discussions with the FDA regarding potential future indications for ILUVIEN. Based on those discussions, Alimera believes it should be able to establish adequate evidence of safety and efficacy for the approval of ILUVIEN for an additional indication of treating either retinal vein occlusion or non-proliferative diabetic retinopathy with a single Phase 3 clinical trial. Alimera is currently evaluating the cost and feasibility of such clinical trials and the market opportunity for each of these indications. Alimera expects to make an announcement in early 2017 regarding a path forward to expand ILUVIEN's label with one of these indications.

Second Quarter 2016 Financial Results

Consolidated net revenue increased by approximately $3.8 million, or 66%, to approximately $9.6 million for the three months ended June 30, 2016, compared to net revenue of approximately $5.8 million for the three months ended June 30, 2015.

U.S. net revenue increased by approximately $3.4 million, or 89%, to approximately $7.2 million for the three months ended June 30, 2016, compared to approximately $3.8 million in the three months ended June 30, 2015. The increase was primarily driven by higher sales volume as ILUVIEN gains market acceptance in the U.S.

U.S. net revenue for the three months ended June 30, 2016 increased 76% compared to the three months ended March 31, 2016.

International net revenue increased by approximately $300,000, or 15%, to approximately $2.3 million for the three months ended June 30, 2016, compared to approximately $2.0 million for the three months ended June 30, 2015. The increase was primarily attributable to increased sales in Germany and Portugal.

International net revenue for the three months ended June 30, 2016 increased 35% compared to the three months ended March 31, 2016.

Consolidated gross profit increased by $3.6 million, or 67%, to approximately $9.0 million for three months ended June 30, 2016, compared to approximately $5.4 million for the three months ended June 30, 2015. Gross margin was 94.2% for the three months ended June 30, 2016 compared to 93.5% for the three months ended June 30, 2015.

Consolidated research, development and medical affairs expenses for the three months ended June 30, 2016 decreased to approximately $3.2 million, compared to approximately $3.8 million during the three months ended June 30, 2015. The decrease was primarily attributable to reduced spend on post marketing studies of ILUVIEN.

Consolidated general and administrative expenses for the three months ended June 30, 2016 increased to $4.0 million, compared to $3.8 million for the three months ended June 30, 2015.

Consolidated sales and marketing expenses increased to $7.5 million for the three months ended June 30, 2016, compared to $6.9 million for the three months ended June 30, 2015. The increase was primarily attributable to an increase in commissions for the U.S. commercial team.

Alimera's GAAP net loss applicable to common stockholders for the three months ended June 30, 2016 was approximately $6.9 million, compared to approximately $8.6 million for the three months ended June 30, 2015. GAAP basic and diluted net loss per share for the three months ended June 30, 2016 was $(0.15) per share on 45,088,072 weighted average shares outstanding, compared to GAAP basic and diluted net loss per share of $(0.19) per share on 44,396,656 weighted average shares outstanding for the three months ended June 30, 2015. GAAP net loss attributable to common stockholders and GAAP basic and diluted net loss per share were affected by certain non-cash items, including loss on the early extinguishment of debt, unrealized foreign currency gains and losses and changes in the fair value of a derivative warrant liability.

Non-GAAP adjusted net loss attributable to common stockholders for the three months ended June 30, 2016 was approximately $7.7 million, compared to a non-GAAP adjusted net loss attributable to common stockholders for the three months ended June 30, 2015 of approximately $11.0 million. Non-GAAP adjusted basic and diluted loss per share for the three months ended June 30, 2016 and 2015 were $(0.17) per share and $(0.25) per share, respectively. Net loss for basic and diluted weighted average shares outstanding attributable to common stockholders per share and non-GAAP adjusted net loss attributable to common stockholders per share were based on 45,088,072 weighted average shares outstanding for the three months ended June 30, 2016 and 44,396,656 weighted average shares outstanding for the three months ended June 30, 2015.

Reconciliations of GAAP net loss attributable to common stockholders to non-GAAP adjusted net loss attributable to common stockholders and GAAP net loss per share to non-GAAP adjusted basic and diluted loss per share are included below in the table titled "Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures."

As of June 30, 2016, Alimera had cash and cash equivalents of $16.6 million. As previously disclosed, Alimera was not in compliance with the liquidity covenant of its debt facility with Hercules Capital, Inc. (Hercules) as measured on June 30, 2016. However, Alimera obtained a waiver of its compliance with the liquidity covenant in July 2016 from Hercules and modified the liquidity covenant so that Alimera must keep at least $20 million in liquidity, consisting of accounts receivables from customers in the U.S. and cash, of which at least $12.5 million must be held in cash in bank accounts that are subject to an account control agreement in favor of Hercules, or that are subject to a first lien perfected security interest in favor of Hercules. In addition, in connection with the waiver, Hercules and Alimera modified the three-month revenue covenant so that it was not measured at the end of July 2016 and reduced the three-month revenue target to be measured at August 31, 2016.

Conference Call to be Held August 4, 2016

A conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results and provide commercial and other business updates. The call will be held at 10:00 AM ET, on August 4, 2016. Please refer to the information below for conference call dial-in information and webcast registration.

Conference date: August 4, 2016, 10:00 AM ET

Conference dial-in:877-269-7756

International dial-in:201-689-7817

Conference Call Name: Alimera Sciences' Second Quarter 2016 Results Call

Webcast Registration:Click Here

Following the live call, a replay will be available on Alimera's website, www.alimerasciences.com, under "Investor Relations."

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in aging populations.

Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measures

Alimera believes the metrics non-GAAP adjusted net loss attributable to common stockholders and non-GAAP adjusted basic and diluted loss per share are useful financial measures for investors in evaluating Alimera's performance for the periods presented. Non-GAAP adjusted net loss attributable to common stockholders and non-GAAP adjusted net loss per share exclude certain non-cash items. These non-GAAP metrics, however, are not measures of financial performance under GAAP

and should not be considered a substitute for net loss attributable to common stockholders or net loss per share in accordance with GAAP and may not be comparable to similarly titled measures reported by other companies.

Alimera's management believes that these non-GAAP metrics are useful supplements for it and investors to Alimera's GAAP financial information because these measures exclude non-cash items which management believes are not reflective of Alimera's operating results. These non-GAAP financial measures also facilitate management's internal comparison to Alimera's historical financial performance and the financial performance of other companies. However, non-GAAP financial measures should only be read in conjunction with financial information reported under GAAP when understanding Alimera's operating performance. For a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure, see the table below.

Forward-Looking Statements

This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for significant growth and market penetration of ILUVEN, that Alimera's refinancing plans will provide additional liquidity and improved financial flexibility, that the waiver will allow Alimera additional time to accomplish its refinancing plans and Alimera’s belief that only one Phase 3 clinical trial will be able to establish adequate evidence of safety and efficacy for ILUVIEN and obtain FDA approval for additional indications of ILUVIEN. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Alimera's ability to close on additional or alternative debt or equity financing in an appropriate fashion, Alimera failing to meet its financial covenants under its amended loan facility with Hercules, which could materially affect Alimera’s commercialization of ILUVIEN, market acceptance of ILUVIEN in the U.S. and Europe, including physicians' ability to obtain reimbursement and seasonality, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at http://www.sec.gov. Additional factors may also be set forth in those sections of Alimera's Quarterly Report on Form10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera.

Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

CG CAPITAL

877.889.1972

investorrelations@cg.capital

cg.capital

ALIMERA SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015

(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
	(unaudited)
NET REVENUE	$	9,557		$	5,776		$	15,358		$	9,714
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(556		)	(376		)	(934		)	(659		)
GROSS PROFIT	9,001			5,400			14,424			9,055
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,205			3,815			6,225			7,144
GENERAL AND ADMINISTRATIVE EXPENSES	4,039			3,821			7,434			7,440
SALES AND MARKETING EXPENSES	7,510			6,925			14,619			14,054
DEPRECIATION AND AMORTIZATION	696			639			1,385			1,211
OPERATING EXPENSES	15,450			15,200			29,663			29,849
NET LOSS FROM OPERATIONS	(6,449		)	(9,800		)	(15,239		)	(20,794		)
INTEREST EXPENSE AND OTHER	(1,177		)	(1,151		)	(2,512		)	(2,273		)
UNREALIZED FOREIGN CURRENCY GAIN (LOSS)	(14		)	143			20			29
LOSS ON EARLY EXTINGUISHMENT OF DEBT	—			—			(2,564		)	—
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	824			2,216			2,343			4,722
NET LOSS BEFORE TAXES	(6,816		)	(8,592		)	(17,952		)	(18,316		)
PROVISION FOR TAXES	(42		)	(4		)	(51		)	(73		)
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS	$	(6,858	)	$	(8,596	)	$	(18,003	)	$	(18,389	)
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Basic and diluted	$	(0.15	)	$	(0.19	)	$	(0.40	)	$	(0.41	)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted	45,088,072			44,396,656			45,046,952			44,372,283

ALIMERA SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)

	June 30, 2016			December 31, 2015
	(unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	16,627		$	31,075
Restricted cash	38			37
Accounts receivable, net	13,257			9,799
Prepaid expenses and other current assets	3,532			2,696
Inventory, net	1,210			1,552
Total current assets	34,664			45,159
NON-CURRENT ASSETS:
Property and equipment, net	2,293			2,553
Intangible asset, net	21,582			22,549
Deferred tax asset, net	227			223
TOTAL ASSETS	$	58,766		$	70,484
CURRENT LIABILITIES:
Accounts payable	$	5,651		$	4,002
Accrued expenses	5,483			3,911
Note payable, net of discount	33,809			31,786
Capital lease obligations	245			234
Total current liabilities	45,188			39,933
NON-CURRENT LIABILITIES:
Derivative warrant liability	472			2,815
Capital lease obligations — less current portion	486			582
Other non-current liabilities	817			834
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Preferred stock
Series A Convertible Preferred Stock	19,227			19,227
Series B Convertible Preferred Stock	49,568			49,568
Common stock	454			450
Additional paid-in capital	302,507			299,376
Common stock warrants	3,049			2,747
Accumulated deficit	(361,903		)	(343,900		)
Accumulated other comprehensive loss	(1,099		)	(1,148		)
TOTAL STOCKHOLDERS’ EQUITY	11,803			26,320
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	58,766		$	70,484

RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES

(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
	(unaudited)
GAAP NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(6,858	)	$	(8,596	)	$	(18,003	)	$	(18,389	)
Adjustments to net loss:
Unrealized foreign currency loss (gain), net	14			(143		)	(20		)	(29		)
Loss on early extinguishment of debt	—			—			2,564			—
Change in fair value of derivative warrant liability	(824		)	(2,216		)	(2,343		)	(4,722		)
NON-GAAP ADJUSTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(7,668	)	$	(10,955	)	$	(17,802	)	$	(23,140	)
GAAP NET LOSS PER SHARE - Basic and diluted	$	(0.15	)	$	(0.19	)	$	(0.40	)	$	(0.41	)
Adjustments to net loss:
Unrealized foreign currency loss (gain), net	—			—			—			—
Loss on early extinguishment of debt	—			—			0.06			—
Change in fair value of derivative warrant liability	(0.02		)	(0.06		)	(0.06		)	(0.11		)
NON-GAAP ADJUSTED NET LOSS PER SHARE - Basic and diluted	$	(0.17	)	$	(0.25	)	$	(0.40	)	$	(0.52	)
WEIGHTED AVERAGE SHARES OUTSTANDING - Basic and diluted	45,088,072			44,396,656			45,046,952			44,372,283

ALIMERA SCIENCES, INC.

CONSOLIDATING STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015

(in thousands)

	Three Months Ended June 30, 2016									Three Months Ended June 30, 2015
	U.S.			International			Consolidated			U.S.			International			Consolidated
	(Unaudited)
NET REVENUE	$	7,208		$	2,349		$	9,557		$	3,804		$	1,972		$	5,776
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(368		)	(188		)	(556		)	(190		)	(186		)	(376		)
GROSS PROFIT	6,840			2,161			9,001			3,614			1,786			5,400
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	2,181			1,024			3,205			1,478			2,337			3,815
GENERAL AND ADMINISTRATIVE EXPENSES	2,323			1,716			4,039			2,179			1,642			3,821
SALES AND MARKETING EXPENSES	5,403			2,107			7,510			4,848			2,077			6,925
DEPRECIATION AND AMORTIZATION	673			23			696			621			18			639
OPERATING EXPENSES	10,580			4,870			15,450			9,126			6,074			15,200
NET LOSS FROM OPERATIONS	(3,740		)	(2,709		)	(6,449		)	(5,512		)	(4,288		)	(9,800		)
OTHER INCOME AND EXPENSES, NET							(367		)							1,208
NET LOSS BEFORE TAXES							$	(6,816	)							$	(8,592	)

	Six Months Ended June 30, 2016									Six Months Ended June 30, 2015
	U.S.			International			Consolidated			U.S.			International			Consolidated
	(Unaudited)
NET REVENUE	$	11,327		$	4,031		$	15,358		$	6,247		$	3,467		$	9,714
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(590		)	(344		)	(934		)	(328		)	(331		)	(659		)
GROSS PROFIT	10,737			3,687			14,424			5,919			3,136			9,055
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,820			2,405			6,225			2,856			4,288			7,144
GENERAL AND ADMINISTRATIVE EXPENSES	4,337			3,097			7,434			4,368			3,072			7,440
SALES AND MARKETING EXPENSES	10,955			3,664			14,619			9,728			4,326			14,054
DEPRECIATION AND AMORTIZATION	1,341			44			1,385			1,180			31			1,211
OPERATING EXPENSES	20,453			9,210			29,663			18,132			11,717			29,849
NET LOSS FROM OPERATIONS	(9,716		)	(5,523		)	(15,239		)	(12,213		)	(8,581		)	(20,794		)
OTHER INCOME AND EXPENSES, NET							(2,713		)							2,478
NET LOSS BEFORE TAXES							$	(17,952	)							$	(18,316	)

EX-99.2

Investor Presentation January 2015 Results Conference Call Second Quarter 2016

Safe Harbor Statement This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, that sales are escalating as practices are being reimbursed regularly and on a timely basis, the opportunity for significant growth and market penetration of ILUVEN and that the data on ILUVIEN will drive growth, that Alimera will be able to refinance prior to the end of the quarter, that Alimera’s refinancing plans will provide additional liquidity and improved financial flexibility, that the waiver will allow Alimera additional time to accomplish its refinancing plans, that Alimera’s belief that the change in payment terms to 90 days in the U.S. will have a positive impact on Alimera’s cash position and Alimera’s belief that only one Phase 3 clinical trial will be able to establish adequate evidence of safety and efficacy for ILUVIEN and obtain FDA approval for additional indications of ILUVIEN. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplate,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Alimera’s ability to close on additional or alternative debt or equity financing in an appropriate fashion, Alimera failing to meet its financial covenants under its amended loan facility with Hercules Capital, Inc., which could materially affect Alimera’s commercialization of ILUVIEN, market acceptance of ILUVIEN in the U.S. and Europe, including physicians’ ability to obtain reimbursement and seasonality, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at http://www.sec.gov. Additional factors may also be set forth in those sections of Alimera’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in this presentation are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this presentation (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. 2 © 2016 Alimera Sciences, All Rights Reserved 2

Q2 2016 Highlights 3 © 2016 Alimera Sciences, All Rights Reserved 3 $2 $9.6M $5.8M Overall Revenue Growth +66% 1Q16 2Q16 EYES TREATED WITH ILUVIEN® TO DATE

4 © 2016 Alimera Sciences, All Rights Reserved 4 United States Significant Growth Record Quarterly Revenue Driven by growth in new accounts as well as increased penetration into historical accounts Increased acceptance of continuous microsdosing 1Q16 2Q16 US Revenue Growth $7.2M $4.1M +76%

5 © 2016 Alimera Sciences, All Rights Reserved 5 Europe Back on Track German Unit Volume Increases 5th consecutive quarter 1Q16 2Q16 Europe Revenue Growth $2.3M $1.7M +35% UK Return to Growth 26% growth over Q1 2016 Portuguese Unit Volume Increases 1st half 2016 > all of 2015

Real World Evidence Real world experience consistent with FAME pivotal trials patients Real world results from 550 patients in two studies consistent with FAME pivotal trials “These data demonstrate that in the real world, ILUVIEN® can improve or preserve vision with a side effect profile similar to that seen in the Phase III FAME studies in the majority of patients with cDMO, even when previous anti-VEGF treatments have failed to deliver a sufficient response and we are very pleased to have it as a treatment option for our patients following NICE approval.”

FDA Meetings Real world experience mimicking FAME pivotal trials Engaged in discussions with the FDA regarding two potential new indications: • Retinal Vein Occlusion • Non-proliferative diabetic retinopathy

Financial Overview Rick Eiswirth, President & CFO

9 © 2016 Alimera Sciences, All Rights Reserved 9 Select Income Statement Data ($000’s) Three Months Ended June 30th, 2016 Three Months Ended June 30th, 2015 Revenue $9,557 $5,776 Gross Profit $9,001 $5,400 Gross Margin 94.2% 93.5% Net (Loss) From Operations ($6,449) ($9,800) Net (Loss) Applicable to Common Stockholders ($6,858) ($8,596)

10 © 2016 Alimera Sciences, All Rights Reserved 10 Select Balance Sheet Data ($000’s) As of June 30th, 2016 As of December 31st, 2015 Cash & Cash Equivalents $16,627 $31,075 Total Current Assets $34,664 $45,159 Total Assets $58,766 $70,484 Total Current Liabilities $45,188 $39,933 Total Stockholder’s Equity $11,803 $26,320

Closing Remarks Dan Myers, CEO

Investor Presentation January 2015 Results Conference Call Second Quarter 2016